1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.
Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 26, 15, 33, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 12 and 2 molecules, respectively.
Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionHuman Papillomavirus (HPV) Associated Cancer - Overview
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment
Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development
Human Papillomavirus (HPV) Associated Cancer - Drug Profiles
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products
Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abion Inc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abivax SA, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis Inc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Anteris Technologies Ltd, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antiva Biosciences Inc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Apimeds Inc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by AstraZeneca Plc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Avalia Immunotherapies Ltd, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Beijing Recreation Guards Biotechnology Co Ltd, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioMed Valley Discoveries Inc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Biond Biologics Ltd, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech SE, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Blue Sky Immunotherapies GmbH, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cellid Co Ltd, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Chain Biotechnology Ltd, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Chengdu Institute of Biological Products Co Ltd, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cue Biopharma Inc, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2020
- Human Papillomavirus (HPV) Associated Cancer - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abion Inc
- Abivax SA
- Advaxis Inc
- Anteris Technologies Ltd
- Antiva Biosciences Inc
- Apimeds Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Avalia Immunotherapies Ltd
- Beijing Recreation Guards Biotechnology Co Ltd
- BioMed Valley Discoveries Inc
- Biond Biologics Ltd
- BioNTech SE
- Blue Sky Immunotherapies GmbH
- Cellid Co Ltd
- Chain Biotechnology Ltd
- Chengdu Institute of Biological Products Co Ltd
- Cue Biopharma Inc
- Cullinan Oncology LLC
- Elicio Therapeutics
- Etubics Corp
- EyeGene Inc
- Genexine Inc
- Gilead Sciences Inc
- Hookipa Pharma Inc
- iBio Inc
- Immunomic Therapeutics Inc
- IMV Inc
- Innovene
- Inovio Pharmaceuticals Inc
- Inthera Bioscience AG
- Iovance Biotherapeutics Inc
- ISA Pharmaceuticals BV
- Ispin Inc
- Johnson & Johnson
- Juno Therapeutics Inc
- Merck KGaA
- OncoNano Medicine Inc
- Onconova Therapeutics Inc
- Oxford Vacmedix UK Ltd
- Papivax LLC
- Pathovax LLC
- Pattern Pharma Inc
- PDS Biotechnology Corp
- Precigen Inc
- Privo Technologies Inc
- Profectus BioSciences Inc
- Rottapharm Biotech Srl
- Rubius Therapeutics Inc
- Shanghai Bovax Biotechnology Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shantha Biotechnics Pvt Ltd
- Shuttle Pharmaceuticals Inc
- TCR Cure Biopharma Technology Co Ltd
- Theravectys SA
- THEVAX Genetics Vaccine USA Inc
- Touchlight Genetics Ltd
- Transgene SA
- Turnstone Biologics Inc
- UbiVac LLC
- Vaccibody AS
- Vault Pharma Inc
- Vectorite Biomedical Inc
- ViciniVax BV
- Vir Biotechnology Inc
- Virion Therapeutics LLC
- Virometix AG
- VLP The Vaccines Company SL
- Voltron Therapeutics Inc
- Xiamen Innovax Biotech Co Ltd
